human reproduction

523 Pages·2016·6.48 MB·English

WWW.HUMREP.OXFORDJOURNALS.ORG
VOLUME 31, SUPP 1 2016
ABSTRACT BOOK
ESHRE 2016 – HELSINKI, FINLAND I 3-6 JULY 2016
human
reproduction
Scan to view this journal
on your mobile device
912978_Cover Abstract Book 2016.indd 1 29/04/16 09:15
Abstracts of the
32nd Annual Meeting of the
European Society of
Human Reproduction and Embryology
Helsinki
Finland
3 to 6 July 2016
Abstracts
32nd Annual Meeting of the
European Society of
Human Reproduction and Embryology
Helsinki, Finland
3 to 6 July 2016
Print copies of the meeting abstracts are provided for Conference Delegates only. However, the abstracts
are available on-line to all Human Reproduction/Update/Molecular Human Reproduction subscribers and
are also freely available to all visitors to the following website www.humrep.oxfordjournals.org, and on the
ESHRE website: www.eshre.eu
Copyright Notice: All abstracts together with the programme, for presentation during the 32nd Annual
Meeting of ESHRE are copyright of ESHRE. These abstracts (or parts thereof) may not be reproduced,
stored, printed or transmitted in any form, or by any means, electronic, mechanical, photocopied, recording,
or otherwise without written permission of ESHRE and the author of the abstract.
Note to the media: All abstracts are strictly embargoed until the time and date of presentation at the
conference.
The opinions or views expressed in this abstracts supplement are those of the authors and do not necessarily
reflect the opinions or recommendations of ESHRE. The abstracts have been reviewed by the Congress
Scientific Committee and revised accordingly by the authors. The selection of abstracts is based on the
scores given by an international panel of peer reviewers.
Dosages, indications and methods of use for products that are referred to in the abstracts by the authors are
not necessarily appropriate for clinical use and may reflect the clinical experience of the authors or may be
derived from the professional literature of other clinical sources. Because of differences between in-vitro
and in-vivo systems and between laboratory animal models and clinical data in humans, in-vitro and animal
data may not necessarily correlate with clinical results.
The investigators of these abstracts have stated in their submission letter that prospective studies where
patients are involved have institutional Ethics Committee approval and informed patient consent, and
that the studies using experimental animals have institutional approval. The Publishers have endeavoured
to reproduce faithfully all of the abstracts as accepted by the Conference Organisers, but can accept no
responsibility for inaccuracies or omissions caused by the late receipt of abstracts.
EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY (ESHRE)
COMMITTEES
Executive Committee Committee of National Irma Virant-Klun (Slovenia)
(2015 – 2017) Representatives Veljko Vlaisavljevic (Slovenia)
(2014 – 2017) Ernesto Bosch (Spain)
Chairman María José Gómez Cuesta (Spain)
Kersti Lundin (Göteborg, Sweden) Thomas Ebner (Austria) Lars Björndahl (Sweden)
Ludwig Wildt (Austria) Pietro Gambadauro (Sweden)
Chairman Elect Frank Vandekerckhove (Belgium) Nicole Fournet Irion (Switzerland)
Roy Farquharson (Liverpool, Greta Verheyen (Belgium) Felix Roth (Switzerland)
United Kingdom) Petya Andreeva (Bulgaria) Basak Balaban (Turkey)
Stefka Nikolova (Bulgaria) Gurkan Uncu (Turkey)
Members Renato Bauman (Croatia) Lyubov Myhailyshyn (Ukraine)
Basak Balaban (Istanbul, Turkey) Patrik Stanic (Croatia) Sheena E.M. Lewis (United Kingdom)
Petra De Sutter (Ghent, Belgium) Mahmut Cerkez Ergoren (Cyprus)
Mariette Goddijn Sozos J. Fasouliotis (Cyprus) Current International Scientific
(Amsterdam, Netherlands) Ursula Bentin-Ley (Denmark) Committee
Georg Griesinger (Luebeck, Germany) Kristiina Rull (Estonia)
Grigoris Grimbizis Sirpa Makinen (Finland) Christopher L.R. Barratt
(Thessaloniki, Greece) Laure Morin - Papunen (Finland) (United Kingdom)
Helen Kendrew (Bath, United Kingdom) Pierre Boyer (France) Frank J. Broekmans (Netherlands)
Borut Kovacic (Maribor, Slovenia) Catherine Rongieres (France) Giovanni Coticchio (Italy)
Nicholas Macklon Lia Chkonia (Georgia) Arianna D’Angelo (United Kingdom)
(Southampton, United Kingdom) Verena Nordhoff (Germany) Johannes L.H. Evers (Netherlands)
Tatjana Motrenko Simic Thomas Strowitzki (Germany) Roy G. Farquharson (United Kingdom)
(Budva, Montenegro) Georgios Pados (Greece) Sofia Gameiro (United Kingdom)
Andres, Salumets (Tartu, Estonia) Michael Pelekanos (Greece) Björn Heindryckx (Belgium)
Rita Vassena (Barcelona, Spain) Peter Fancsovits (Hungary) Andrew Horne (United Kingdom)
Péter Kovács (Hungary) Helen J. Kendrew (United Kingdom)
Immediate Past Chairman
Edgar Mocanu (Ireland) Kersti Lundin (Sweden)
Juha Tapanainen (Helsinki, Finland)
Aonghus Nolan (Ireland) Willem Ombelet (Belgium)
Eitan Lunenfeld (Israel) Guido Pennings (Belgium)
Special Interest Groups Chair
Giedre Belo Lopes (Lithuania) Felice Petraglia (Italy)
Cristina Magli (Bologna, Italy)
Lucia De Santis (Italy) Siobhan Quenby (United Kingdom)
Zoranco Petanovski (Macedonia) Heidi Roijemans (Belgium)
Central Office
Valentina Sotiroska (Macedonia) Françoise Shenfield (United Kingdom)
Christine Bauquis
Susana M. Chuva de Sousa Lopes Claudia Spits (Belgium)
Veerle De Rijbel
(Netherlands) Juha S. Tapanainen (Finland)
Veerle Goossens
Velja Mijatovic (Netherlands) Bruno Van den Eede (Belgium)
Nathalie Le Clef
Anette Bergh (Norway) Antoine Watrelot (France)
Karen Maris
Nan Brigitte Oldereid (Norway)
Catherine Plas
Anna Janicka (Poland) Local Organising Committee
Erika Mar Rodriguez Raes
Robert Spaczynski (Poland)
Heidi Roijemans
Monica Marina Dascalescu (Romania) Juha Tapanainen
Bruno Van den Eede
Bogdan Doroftei (Romania) Aarne Koskimies
Sarah Vandersteen
Nebojsa Radunovic (Serbia) Anne-Maria Suikkari
Titia Van Roy
Lela Surlan (Serbia) Aila Tiitinen
Ine Van Wassenhove
Ana Ivanova (Slovakia) Timo Tuuri
Nathalie Vermeulen
iii
National Committee Hannu Martikainen Miia Savander
Laure Morin-Papunen Niklas Simberg
Johanna Aaltonen Sirpa Mäkinen Eeva-Liisa Sirviö
Leena Anttila Sinikka Nuojua-Huttunen Viveca Söderström-Anttila
Ralph Ashorn Mauri Orava Helena Tinkanen
Tiina Hakala-Ala-Pietilä Marjut Otala Tomás Candido
Oskari Heikinheimo Mirka Paavilainen Annika Tulenheimo-Silfvast
Christel Hyden-Granskog Paula Peltopuro Eero Varila
Liisa Häkkinen Antti Perheentupa Zdravka Veleva
Esa Korkeela Terhi Piltonen Elina Vuori-Holopainen
Kaisu Luiro-Helve Anna-Kaisa Poranen
Annamari Lähteenmäki Kari Ratsula
Harri Mankonen Marita Räsänen
Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the organisers for any
injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any meth-
ods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, we recommend that
independent verification of diagnoses and drug dosages should be made.
iv
human
human
hhuummaann
huremparnoduction
reproduction
rerepprorodduucctitoionn
reproduction
Editor-in-Chief
Professor J.L.H. Evers (Netherlands)
Editor-in-Chief
Deputy Editors
A. Van Steirteghem
R. Sharpe (United Kingdom)
Editor-in-CEDhEdeii.e tpSofuorEtm-yidni gEi-tlCodiarhint-ioaien rf(-sICtahlyie)f
A.VEa.n SASo.tmVeiairgnteligSahtneeaimrteghem
A.Van SteiMrte. gvhaenm Wely (Netherlands)
DeJp. uLt.y DHeE.p dEuivttyoerrEssditors
Deputy EditoArsssociate Editors
R. Sharpe
P.G.CrPo.sGig.Cnarnoisignani
P.G.Crosignani
J. Abbott, Australia T. Freour, France A. Ludwig, Germany H. Stern, USA
AsJs.Loc.Hia.tEeJ. vELe.drHsit.oErvsers
T. Adriaenssens, Belgium J. FuglsaJn.gL, .DHe.nEmvarekrs J. Malejczyk, Poland I. Sundstrom-Poromaa,
C. Amorim, Belgium A. Galhardo, Portugal R.SharRpe.BS.h MacrKpeinnon, Switzerland Sweden
R. Abir, Israel R.SharGp.e Harton, USA A. Palumbo, Spain
B. Ata, TurkeyC. Y. Andersen, DSe.n Gmaamrkeiro, UnitedEA .K sHisnaogrvcdiiolalmAet,es UsEoSAcdiAiatt.o eMrsEeidnhitaordrts, CG.e Premtrayn, yUK S. Sunkara, United Kingdom
V. Baker, USAA.-M. Andersson,K D. eGnAemmaszrskeolcl-iDaatneieElEsd.s oHitnao,u rzsman, HunJg. aMryersereau, UCS. APlancha, PortugalJ. G. Thompson, Australia
M. Bedaiwy, CAaCn..Y aB.dAaalnedne,C rU.sYeKn.A,DndeSenrwmseeandr,keDnenmark E.HEa. uHzumgEahn.eH,sHa, uCuznamgnaaanrdSy,a.H Puanlgoamryba, ItCaS.l.Py Peturyb,liUcCoK.vPeert,r yU,KUK A. Tiitinen, Finland
RC. .BYe.Ahnr,d Geresermn,aFADn. .eByBneamllveanar,,k ABU.eKBlgailuenm,MUE.K .GHöatutzem, Gane,rHmuaEnn.gHyLau.r gyHhuelsEl,,. CAHauunsgtahrdaeasli,aCCC.aP.n ePatlrdayan,cUhKa, PoCCr.tP.u lRganaacclhoawC,.sPPkloyar,n tUcuhgSaaA,lPoGrtu. gTaolft, Denmark
PAO. B..BBraaalsdesyno,,, UUUSKSAALOF...BBBejaolsvrsano,d,BOFaUh.e.BSBllg,Ae aiSlsuvwsmaoe,,dRBUe.eELn SlG..gAHHiruuuumglelhm,eAmsu,seCtrr,aa nGlaiLBaed..rHHaPm.uu Jalplonp,uyeAarLBuntzs..nHH,terAuuat,lupl liFsp,atreArariutanzsCScG,t.re.APPa. uullQiabsantulricicihnaoanv,,e PrU,oSUrtASCKuP..g.PR aRualbaclyoi,cw oFsSCvrk.ae.PyRrnu,,acbUUceloiSKcwAosvkeyr,,UUKSK. AToulis, Greece
SF. .BBerolvwan,,B UelSgiAuDLm..B Bjoordnrdi,aL Hh.Blu,jnSogwrnaedrdDyaeh.nB lH,.HSawunpeddpeeelsnrtmz,aAnu, PsAt.rMuLisa..tW rKa.ulJimaaPn.asMrs,e .SWnws,.eJNadneeCstnJhs..e eRRnralsaac,monNwdaeslsthkhoyer-,lSUaaLnSPnd.A.Rt soSisec,nr iPzvioe,LrnIt.t,Rua UgliyeaKnlzi,ItalyK. Tremellen, Australia
OL. .BBjuokrnudlmahel,z,S wUOOeS..d BABe.n CChhrrisiOstit.aBian.nsCeshenrn,iM,sD tDiPe.a ne.nHMmnsame.anWnras,kr.eDJknae,nn sAmsueasnrtsJkr,.aJNoSlihe.a ntLhsaeoirnrlJd,a.J,nU oUdShsKAnson,LUA.SR.A iRenozmi,aIntaol,y NKKe.tS.h eSerremlramonnKod,n.sBS, eeBrlgmeiluogmniu,mBelKgi.u Umpson, USA
J.O C.Ba.rClohsr iCstiaasntsileClPno..,D, DDSeepeB naGmoineeaPyrr,.tDkeNre,e tSBhwoereiDtlrza,.Je nN.HrJdleosaathpnhnadesrnolganan,mdUsaS,A UP.nJSoi.tu eLadna nnePgt.l,JooFiusr,aa nCnncaeent,aKLFd..Sar Raernomcmeobn,auBtesl,g AAiAu.uSm. shNter.la lSilnihaAge,.lSlNihneegwl,l iNZnegea,wlNa ZneBewda. lZUaenramdlaannd, Turkey
NP.. DCeatBalodeor,, NUeStLhCAe.. DrDlaeensGdsseoylCltee.D,r ,FeSrGwaneitcKyzeteiePrnrl.,gaJoSdnuwdoamintzneertl,aFndraLn.cKJe.u Lmaavre,LnS.,K wNueemdtehaner,rlSaAGwn.S.ed dhSseeanlcliknsg,, ANueswYtYr.Za.S elShiaauhl,aunU, dUYSAS.SAhu,USA L. Van Landuyt, Belgium
GCCAW.. ..CDC.DDreoeoittGnViccdheocoylsher,tpieyBo,r, ,,eNA lSIgeutAPwAWMati.shu i..ltD.t .DemyrEDDzraeeelloelrvaTin lVrnVaadoodonoouessdAWMsyrk,,p,.h B. .DB,EBDyeNee,leollgelUTgnVgtidiohuKiouuouemFJsmm.rrk., p lLSShdHBa,y..e.neLLKNe,ndllaageUu sminHtimrhuKgdeaemal,rorrrhUtl,ioasoSK,gnrwCsd, tseNa, dnNSSJeea.t..LneLLhdRGtaaeaahv..rinSeBrelgdra.n. ll, nL,oaLUdiNSSJenos.sgK..,dLeuLLrtCsiahoaasvaine,,r enrgUUdnlal,a,oSSdnUiNAAasdK,eYJEsHK-tC.h.PSS..ae. ohSSSnrmluiaccaf,dhhfingrUaaldolitiSseita,AepnFn,a r,U, aUISnJEMtEC-aScA.PS.le.A.Sy . oSSStmeiopfpmifihtgrsoeil,JEMgiin a-,Bl.sPniS.FoaeS.aoSnrnlt,gmea,iaIfipn,Utfui ahcgrImSoleetlyaiAina,lsnyFoanr,aCP,I.nUt .aVc VSleyiAegrahnaoa,k I,t aNleytherlands
AM. .DEellTboauekreh,y B,UeWHlKg..F iD.uEomsncdooHbra.prF-,. MENsoecrtohrJebe.a arJJlrl.eaa-L,MmnaSdvoepsesrarn,ie ,nNaNleeew,thS ZepreaRlaia.nSlnMa.dLn.sLdegurdoRw,.SUig.SL, AGegerrom,MJUa.n .SSSyAtheapwh,e nAsuosnt,rAaUMl.SiSa.At SratnedpehAlel.,nSSstrowanne,dd UeenlSl,ASwJ.e Vdeisnser, Netherlands
CH. .DF.iEaszc-oGbaarrc-MiaJE,o. rS.ErFwerhaaemlgdeoc,euknSlEepi,,.a FGUirnaeKgrmouaAlni,.Ry UK.SKa.Lmeigsrcoh,kUe,S AGMe.rFLm. uMadwnayciMgC,a.GLllueudrmmw,ai gUn,yAKBG..Se Strrmoannadnneytallg,,S GwNeeAdr.Se.m nuSagtnrinayonN,dJe.Sallup, gaSinwnoe,dJeanpLan. Wise, USA
FJS.EMKD.. DD...DF.GGFroryeeoramievmugtrzeloi,zi,nt useS,U,gl loFilGu,S-urDeAUratzehanK,en cMHAAcMKDGSieeefp.......rl GGG FasFFiEsc.eorrie olniiamEuret nTlzlssiz,i,onicsenSUu,,oMKDGlg wlkIGbS-e...t.hGGGeDaAaFrrdy,releorra-,yeiieGm nMuetnUczilsezeei,oiKrselnKMMUm,rslgrslGSa.e-eSFGMo.. D AnarKrn..WL.,MMel.yMa,LeieaGnrS, iaucao LkisewcSeednsnerCalpmew,tmgss gdaasEiaceaoeloigarlhnsnmnn,u,rtky,moGdUeeS,nre,, Syw DirAUGaFSGL,mee..A.Ked.MMManMEMHurenmmns.aio.oy .s tcM raMrsnaMCiamrtnngaklae-cyierolPFSGLraGbrltmau..,.e.aMMMoMpmsUeiwux,raio ,oSsyn,Bcar snAU,eBCinemtnnAKg,lea- ,geouUllPrlgFimsauu,NRABSitiWAGpmurmUneA....uamSTrlSSne,eSaynluruuadioAUn,eamlrgtrnndlclAKeiiaa-,lnvujitY-nFofazsNfoniy,tiesrnu,Ji,,alknaCaUGloipgnaaKral dneaSRABZnaNRAeio... .dcVSTSS...nea uuaSapSS, lrtniuuuClcleialgtlvdsalcitiifazeslnnvfRABZniri,eaosa f,...fS,.,n,VdSTSeC pUG,Jau,ua au aaClrKrtUnlynclpeaial,aKvdeaitndcRfazenafenaireesd,pS,,aCupUGbuaKrlyneic,aedcRoeaefpublicof
G.Griesinger,GMLe.r.G mFuariinltbyze,r LUt,.GSCAuainlbaedrat,LC.Manoardina-PapunMen.,SMF. uiMnnlriaosnMs,dmU.MeSrAu, nUroS,AUZ.SVAanderSpuy,BRS. eo TpuautlhbaltAizcfirsoSi,cfo GautrheeAcferica
L.Guilbert,CanMSa-d.W aG.GauusotS,e-rCW, hAi.uGnsautroi,aCMh.iMnaunro,USAZ.PSG.Nt MaatgoiysnZ,tt.giUPcoS.aNmAlae Agryyd,, vAUiuSsSsAotorruaytlhi aBAofraicradAZ.V. VaannL daAenr.gV SeanpnduoyLn,a cSnkogtu,etnBhde Aolgnfircuikcmta,Belgium
S-W.GuOo., BChasinsDKao.. H(GCaoamunmlaisdaK,ra .Gb)He r aregme,cmAeaursZbtre.aPrgl.iNS,a.aA gRuyso,tbrUaelSritAasA (.UNZK.aPp). , N TaAhge.yNN, aUept,ShAeTrhleaAnN.SdVes. taMhneriLslaasnmngdeesrn d(CUoP..nV SVcAekentr),ec tBeisleCl,li.gnGViiur,e emnIeteacteliys,GCr.e Veceenetis (Greece)
K.HammarbergGG,A.. HGuasrtrirteoasnliiG,nagU.HeSraA,r Gtoenr,mUAaS.nNAyap,TheNetLh.eMArl. aNNnedalpssL,o .NnM,eU.tNhSeeArllsaonnCd,.sVUeSnAetis,GreePWc.eV. eVrecerplloPine.Vis,te,I rtBaceleylllginiui,mItaly
G.Harton,USASE..-HWa.r vGiluleEo,,. HUCaShrAivnialle,LU.MSA.Nelson,USDA.NV.o NguoerFiDdroah.N,ouFfonfrg,da uGnienceirergaPm, .EaVFnrdeyaricntecolelrini,ItaLlLy.W. Wiltioltno,LnA.,W uAsuitlrstoatrnlai,aliAaustralia
EM.H.Haerdvgileler,AUuSstAKrMa.l. HiHaeadmgmeMraAr.Hbuesertdrgga, elAirauADVsut..rNNsatoorlaigradluiheaoirfaf,,GFreVarnm.NLcae.on rPydahlo,V fUf.N,RSGAo.Gredr.hm EoafdnfLTw,y..GWWareiidrlstmscohanmn,yaAnuns,trTGaT.leW.i raWmisaicsnhcymhTma.Wnanni,sncG, hGemremarnamnna,ynGyermany
EditEodriEEtomdri etEormirtuEesrmiteiriitus
EditorEmeriEtudsitor Emeritus
A. Van Steirteghem D(B.Hel.gBiaurmlDo)w. H . B a r l o w D.H. Barlow (UK)
D.H.Barlow D.H. Barlow
MaMnaagniMnaggainEnadggi tiEnodrgitEodritor
ManagingEdMitoarnaging Editor
A.C.WilliamsA(E.ACSH..CWR. iEWllAiJialo.lmCAiua.sr.mWCn(asE.i l lWs(SlE)iHaiSmlRlHisEaRm(EJEso S Ju(HoUrnuRKarnEl)sa)Jlso)urnals)
AssistantMaAnAsasAsgisssiitnssatigsnaAtntEastMdns Miitsta toManarnnaaagtngiMnainggaginEn Eagdgd iEtiinotdorgirtEodrsitor
K.R.WatkKin.Rs.( KEWS.aRHt.kWRinEast JKk(oUi.nuRKsr.nW)(a E la sS t) Hk i Rn sE ( JE o S uJHurnlRiaeEl sH)Jaosutrinnaglss )(UK)
K R Watkins
EditoriaEldAitdomriainliAstdramtoinristrator
EditorialAdminEidstirtaotroiarl Administrator
K.EEd.PiatorkrKsia.(EEl .ASPHadrRmksEi(nJEioSsutHrrnRaatElos)rJournals)
K.E.Parks(ESHREJournaKls. )Parks (UK)
K.E. Parks
EditorialOffiEcdeiEtodriitaEoldrOiiatfolfi rOcieaflfiOceffice
ESHREJournaElsSE,HS5RHMERiEJlElo SJYuoHraunRrradnEl,sa,CJls5oh,u iM5lrdn MiealErllliseYld,ly i5aY,traoMCdrr,daiiCm,la lChlbY ihOsla,dilrfeCddfireB,lcerC2elye3h,yiC,8l dCBaemaArmlbesyb,,sC,C CBamB232b3s8, B8CABBA2,3 U8KBA
Tel: 44(0)19T5e4TlT:e2elþ.1l:. 24:+ 44+4T044(e40 4l;(:) 0(1Fþ)09a1)54x9144:59452( 04124)E 214124S291(04H502404)4R;410E2,9F 41F 5aJ,2a4x oFx4:ua2:0þr x1+4n:24;a4 3+4l4Fs54 a,((9 40x05; ):) (M11E0þ99-)im5541ll4449 aY 5i22(al401:1r )d22e21,33d 19C55i25t9h9o34;i;r5 liE2dE9a1e-l;-m@ r2mEl3eaah-y5imiul,9l ::mC ;aeeiaEadldm:ni- itmretobeodrsaprii,iiart aloCol:l@rd@Beiuadh2hcliu3@ttuiom [e-mail]..ucnutk.kicoon..ucko.uk
þ þ
Published for the
EuropeanSocietEyuoErfouEpHrPoeuuuaprbmonelapEiaSsnenuho aSrecRnoodi peeScfpteiboyoearyctronyoidOte fShoutBxyHeofcPy f tcHuuooPi ioObmrfeuud nltbbmHxiayslyUfanuiahoonsnmneORhrfd ddieRxvaeHP EdnUfpfeeu uoomr rpfnRbmsrorordbiilodrettvia rhydsuptUeynhheucrroPeneotscRlirdiitdooetveiyuognsfpe cnsoyrrPa,t sroianridotetndhyunsdesc E PaE,tmnirmoedbnsb srEra,yymnoodlbloorEggyymyolborgyyology
byOxfordUniversBiyty OPxrOfeosxrsdf,o UOrdnx,ifvUoeOrKrdsx,i ftUoyr KPdr,eUssK,
Oxford,UK Oxford, UK
ThecoverTohfeHcouvmearnofRHepurmodauncRtieopnroshdouwctsiohnissthoonwesacheitsytolanteioanceintytlwatoiohnuimnatnwgoehrumminaanlgveersmicilnea(lGvVes)icstlaeg(eGoVo)csyttaegse.Tohoecyutpeps.eTrphaenueplspesrhopwanaenlsesahrolyw-satnageearly-stage
ThecoverofHumanReproductionshowshistoneacetylationintwohumangerminalvesicle(GV)stageoocytes.Theupperpanelsshowanearly-stage
GVoocytGeVwiothocaynteonw-istuhraronuonnd-isnugrrnouucnldeoinlugsnsutcalienoeldufsosrta(Ain)edchfroorm(Aat)inch(DroAmPaIt;inbl(uDeA)aPnI;db(lBu)e)haisntdon(eBa)cheitsytolanteioance(atynltai-tHio4nK(a1n2tai-cH;r4eKd)1.2Naco;teretdh)e.rNegoitoenthseregions
GVoocytewithanon-surroundingnucleolusstainedfor(A)chromatin(DAPI;blue)and(B)histoneacetylation(anti-H4K12ac;red).Notetheregions
ofintenseofchinrotemnasetinchsrtoaimniantignisntasionminegairneasso,mwehaerreeaass,owthheerrseasshoowthenrosashcoetwylantoioance(Cty;laotvioenrla(Cy);.oTvheerllaoyw).eTrhpeanloelws,erofpaanmelos,reofdeavmeloorpeeddeovoeclyotpeedwiotohcaytewitha
ofintensechromatinstaininginsomeareas,whereasothersshownoacetylation(C;overlay).Thelowerpanels,ofamoredevelopedoocytewitha
surroundisnugrrnouucnldeiunsgsntauicnleedusfosrtacihnreodmfaotrinch(rDo)maantidnh(iDst)onanedacheistytolanteioance(tEy)l,atsihoonw(Em),orsehocwonmdeonrseecdocnhdreonmseadtinchtrhoamnaintinthtehaenarilny-tshteageearoloyc-syttaege(aoboocvyet)e,(above),
surroundingnucleusstainedforchromatin(D)andhistoneacetylation(E),showmorecondensedchromatinthanintheearly-stageoocyte(above),
althoughathltehoouogchyttehestiollochyatsessotmillehaacsestyolmateedaccehtryolamteadtincharsomshaotwinnaisnsEhoawnndionveErlaanyd(Fo)v.eFrloarym(Fo)r.eFdoertamilosrseedeevtaainlsdseeneBvearngdeetnaBl.,erpgp.et11a8l.1,–pp1.19101.81–1190.
althoughtheoocytestillhassomeacetylatedchromatinasshowninEandoverlay(F).FormoredetailsseevandenBergetal.,pp.1181–1190.
v v
Contents
Oral Presentations
Monday 04 July 2016
O-001-O-002 Session 01 – Keynote Session.....................................................................i1
O-003-O-008 Session 02 – Oocyte handling/activation and embryo culture.............................................i1
O-009-O-014 Session 03 – Art in the difficult patient..............................................................i4
O-015-O-020 Session 04 – Sperm selection and preparation for ART .................................................i7
O-021-O-026 Session 05 – Advances in understanding of endometriosis and endometrial biology...........................i9
O-027-O-032 Session 06 – What does genotype mean to the embryo?................................................i12
O-033-O-038 Session 07 – Optimizing ovarian stimulation ........................................................i15
O-039-O-040 Session 08 – Understanding human reproduction through stem cells: tales of translational discoveries...........i19
O-041 Session 09 – Data reporting session ...............................................................i19
O-042-O-043 Session 10 – The early embryo - genetics and development.............................................i19
O-044-O-045 Session 11 – Paramedical invited session - Laboratory.................................................i19
O-046-O-047 Session 12 – Optimisation of the monitoring of ovarian s timulation ......................................i20
O-048-O-049 Session 13 – Cellular interactions in oocyte physiology................................................i21
O-050-O-051 Session 14 – What is the problem with anonymity in donor conception?...................................i22
O-052-O-055 Session 15 – Paramedical 1 - Nursing..............................................................i22
O-056-O-060 Session 16 – Preimplantation genetic screening and mitochondrial DNA ..................................i24
O-061-O-065 Session 17 – Benchmarking ART .................................................................i27
O-066-O-070 Session 18 – Complications and consequences.......................................................i29
O-071-O-075 Session 19 – Loss and distress in infertility. Treatment and beyond.......................................i32
O-076-O-080 Session 20 – Ovarian tissue culture, cryopreservation and grafting .......................................i34
O-081-O-085 Session 21 – Poor responders: new hope?...........................................................i36
O-086-O-087 Session 22 – The new genetics frontier: up close and personal...........................................i39
O-088-O-089 Session 23 – Reproduction and rhythmicity .........................................................i39
O-090-O-091 Session 24 – Consequences of an extra X-chromosome – lessons from mouse models and consequences for children...i40
O-092-O-095 Session 25 – Paramedical 2 - Laboratory ...........................................................i41
Tuesday 05 July 2016
O-096-O-097 Session 26 – Do IVF patients deserve standard treatments? ............................................i42
O-098-O-099 Session 27 – Epigenetic remodelling in embryos: view on expression by magnifying glass....................i43
O-100-O-101 Session 28 – ASRM exchange session - Special considerations for ART in patients with sex
chromosome aneuploidy: Klinefelter syndrome and Turner syndrome ..........................i44
O-102-O-103 Session 29 – Paramedical invited session - Nursing ...................................................i44
O-104-O-109 Session 30 – IVF laboratory quality and strategies....................................................i45
O-110 Session 31 – Live surgery session.................................................................i48
O-111-O-116 Session 32 – Endometrial receptivity - what’s new? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .i48
O-117-O-122 Session 33 – Deep sequencing the embryo..........................................................i51
O-123-O-128 Session 34 – Reproductive epidemiology, socio-cultural aspects and health economy 1.......................i54
O-129-O-134 Session 35 – AMH: the plot thickens ..............................................................i56
O-135-O-137 Session 36 – European and global ART monitoring session.............................................i59
O-138-O-139 Session 37 – Update on ultrasound imaging.........................................................i60
O-140-O-141 Session 38 – Reproductive endocrinology/Early pregnancy.............................................i61
O-142-O-145 Session 39 – Paramedical 3 - Nursing..............................................................i61
O-146-O-147 Session 40 – The need for oxygen in IVF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .i63
O-148-O-149 Session 41 – Insulin sensitizers in reproduction ......................................................i64
O-150-O-153 Session 42 – Embryo and double gamete donation (Patient session) ......................................i65
O-154-O-156 Session 43 – Legislation and economics of the EU Tissue & Cell landscape................................i66
O-157-O-158 Session 44 – Paramedical invited session - Nursing ...................................................i66
O-159-O-163 Session 45 – Embryo (epi)genetics and miRNAs .....................................................i67
O-164-O-168 Session 46 – The uterus in infertility...............................................................i69
O-169-O-173 Session 47 – Trophoblast and endometrial cross talk ..................................................i71
O-174-O-178 Session 48 – Safety and quality in ART 1...........................................................i73
O-179-O-183 Session 49 – Stem cells.........................................................................i75
O-184-O-188 Session 50 – Effects of age and health on semen parameters and sperm DNA integrity .......................i77
O-189-O-192 Session 51 – Oocyte and sperm quality.............................................................i80
O-193-O-196 Session 52 – When sperm are the limit.............................................................i82
O-197-O-200 Session 53 – Genetic factors in infertility...........................................................i84
O-201-O-204 Session 54 – Reproductive surgery ................................................................i86
O-205-O-208 Session 55 – Female fertility. New and renewed ideas .................................................i88
O-209-O-212 Session 56 – Ethics and law......................................................................i90
Wednesday 06 July 2016
O-213-O-214 Session 57 – Molecular elements in male infertility...................................................i92
O-215-O-216 Session 58 – Endometrial injury prior to embryo transfer in IVF.........................................i92
O-217-O-218 Session 59 – Paramedical invited session - Controversies - “Embryo transfer exclusively in the frozen cycle?” ....i93
O-219-O-225 Session 60 – Embryo time-lapse microscopy ........................................................i94
O-226-O-232 Session 61 – Novel markers in reproductive endocrinology.............................................i97
O-233-O-239 Session 62 – Oocyte and embryo cryopreservation...................................................i100
O-240-O-246 Session 63 – What sperm can do more than fertilize .................................................i103
O-247-O-253 Session 64 – Safety and quality in ART 2..........................................................i106
O-254-O-260 Session 65 – Endometriosis in the clinic...........................................................i109
O-261-O-262 Session 66 – Basic science of early pregnancy ......................................................i113
O-263-O-264 Session 67 – ASRM/Society for Reproductive Endocrinology and Infertility: Primary Ovarian Insufficiency:
The problem and possible solutions....................................................i114
O-265-O-269 Session 68 – Embryo development and non-invasive assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .i114
O-270-O-271 Session 69 – Endometriosis, how does it hurt?......................................................i117
O-272-O-276 Session 70 – Screening and predicting ............................................................i117
O-277-O-281 Session 71 – The compromised ovary.............................................................i120
O-282-O-286 Session 72 – The surrogate and prospective parents experience of surrogacy ..............................i122
O-287-O-291 Session 73 – Gonadotoxicity and fertility preservation................................................i124
O-292-O-296 Session 74 – PCOS ...........................................................................i127
Posters Presentations
P-001-P-095 Andrology ..................................................................................i131
P-096-P-142 Early pregnancy..............................................................................i170
P-143-P-271 Embryology.................................................................................i191
P-272-P-362 Endometriosis, endometrium, implantation and fallopian tube..........................................i246
P-363-P-367 Ethics and law ...............................................................................i285
P-368-P-471 Female (in)fertility............................................................................i287
P-472-P-492 Male and female fertility preservation.............................................................i332
P-493-P-495 Paramedical - Laboratory ......................................................................i341
P-496-P-502 Paramedical - Nursing.........................................................................i342
P-503-P-548 Psychology and counselling ....................................................................i345
P-549-P-587 Quality and safety of art therapies................................................................i365
P-588-P-659 Reproductive (epi)genetics .....................................................................i382
P-660-P-753 Reproductive endocrinology ....................................................................i413
P-754-P-772 Reproductive epidemiology, socio-cultural aspects and health economy ..................................i454
P-773-P-783 Reproductive surgery..........................................................................i462
P-784-P-794 Stem cells...................................................................................i467
vii

Abstracts of the 32nd Annual Meeting of ESHRE, Helsinki, Finland, 3 July – 6 July, 2016
Oral Presentations
factors – including maternal characteristics – affects the developing fetus via a
INVITED SESSION number of pathways resulting in the programming of future health outcomes.
Early life programming has mostly been studied in relation to long-term
SESSION 01: KEYNOTE SESSION
health outcomes in relation to being born with a small body size. However,
Monday 04 July 2016 Hall 1 08:30–09:30 several more recent studies have been reporting associations between mater-
nal obesity and later health outcomes in the offspring. The prevalence of over-
weight and obesity are increasing worldwide and within the European Union
about one-third of women of reproductive age are overweight, and every fifth
O-001 Human reproduction keynote lecture – Modifiable and
is obese. Maternal obesity is associated with immediate adverse maternal and
non-modifiable risk factors for poor sperm morphology
neonatal outcomes including an increased risk of congenital defects and mis-
A.A. Pacey1 carriage. Further there is increasing evidence suggesting that maternal obesity
1University of Sheffield, Oncology and Metabolism Jessop Wing, Sheffield, UK also has long-term consequences for the offspring’s later health and wellbeing.
Maternal obesity in pregnancy has been associated with an increased risk
Abstract text
of premature death in adult offspring. Further based upon findings from the
The Chemicals and Pregnancy Study UK (CHAPS-UK) is a comprehensive
Helsinki Birth Cohort Study it has been shown that higher maternal pregnancy
investigation of >2,200 men attending 12 fertility clinics across the UK for their BMI was associated with an increased risk of cancer, cardiovascular disease,
first semen analysis. In two papers published in Human Reproduction in 2012
and type 2 diabetes, among the offspring. The association with type 2 diabetes
and 2015, the data was used to investigate how modifiable and non-modifiable
was stronger in women, consistent with the transmission of type 2 diabetes
lifestyle factors were related to low motile sperm concentration (<12 million from the mother to her daughters being stronger than transmission to her sons.
motile sperm per ml) and low sperm morphology (<4% normal forms), respec- Maternal BMI was positively associated with BMI in the offspring as ex-
tively. This is important because whilst many studies have claimed that men’s
pected. Higher maternal BMI was associated with less favorable body composi-
lifestyle can affect semen quality, the evidence is weak with studies often un-
tion in the offspring. There was a significant interaction between birth weight
derpowered and poorly controlled. The design of CHAPS-UK addresses many
and maternal BMI on offspring body fat percentage in adult life. In mothers
of these criticisms recruited eligible men, aged 18 years or above, were part of a
with low BMI, a higher offspring birth weight was associated with lower fat
couple who had been attempting conception without success following at least
percentage, while among those with maternal BMI in the highest fourth, higher
12 months of unprotected intercourse and also had no knowledge of any semen
offspring birth weight predicted higher body fat percentage in adult life. Our
analysis before being enrolled.
findings suggest that a disadvantageous body composition is programmed in
In our 2012 paper we found that risk factors for low motile sperm concen-
early life, as a consequence of prenatal growth and maternal adiposity. This
tration, after adjustment for recruitment centre and confounding factors, includ-
may in part underlie the association between maternal obesity and later car-
ed a history of testicular surgery [odds ratio = 2.39, 95% confidence interval diometabolic health in the offspring. These findings support the importance of
(CI): 1.75, 3.28], being in manual work [odds ratio (OR) = 1.28, 95% CI: 1.07, prevention of overweight in women of childbearing age.
1.53] or not working (OR = 1.78, 95% CI: 1.22, 2.59) and having black ethnic- One plausible explanation for an association between maternal obesity, which
ity (OR = 1.99, 95% CI: 1.10, 3.63). Conversely, men who wore boxer shorts provides adverse intrauterine experiences, and later health is in utero programming,
(OR = 0.76, 95% CI: 0.64, 0.92) or who had a previous conception (OR = 0.71, which may work through environmental, genetic, and epigenetic mechanisms.
95% CI: 0.60, 0.85) were less likely to be a case. No significant association was
found with smoking and alcohol consumption, the use of recreational drugs, a
high BMI or having a history of mumps or fever. By contrast, in our 2015 paper
we found that risk factors for poor sperm morphology, after adjustment for cen- SELECTED ORAL COMMUNICATIONS
tre and other risk factors, included: (i) sample production in summer (odds ratio
SESSION 02: OOCYTE HANDLING/ACTIVATION AND EMBRYO CULTURE
(OR) = 1.99, 95% confidence interval (CI) 1.43–2.72); and (ii) use of cannabis
in the 3 months prior to sample collection in men aged ≤30 years (OR = 1.94, Monday 04 July 2016 Hall 1 10:00–11:30
95% CI 1.05 – 3.60). Men who produced a sample after 6 days abstinence were
less likely to be a case (OR = 0.64, 95% CI 0.43–0.95). No significant associa-
tion was found with BMI, type of underwear, smoking or alcohol consumption,
O-003 Influence of the duration between removal of cumulus cells and
or having a history of mumps.
oocyte retrieval on fertilization and embryonic development
For both analyses, the data had been collected blind to outcome and so expo-
sure information should not have been subject to reporting bias. This is a major Y. Ishikawa1, M. Inaba1, H. Matsumoto1, S. Mizuno1, R. Mori1, M. Ida1,
strength of the study. In conclusion, both of our analyses of the CHAPS-UK A. Fukuda1, Y. Morimoto2
data suggest that common lifestyle choices generally make little contribution 1IVF Osaka Clinic, Department of Ob/Gyn, Osaka, Japan
to either low motile sperm concentration or low sperm morphology. Therefore, 2HORAC Grand Front Osaka Clinic, Osaka, Japan
any delay to assisted conception in order to make poorly evidenced changes to
Study question: The aim of present study was to investigate if the timing of
lifestyle to improve semen quality is not recommended.
cumulus removal post retrieval would be a critical on fertilization and embry-
onic development.
O-002 Long-term consequences of maternal obesity on the Summary answer: The present study suggested sufficient time to culture oo-
health of offspring cytes with intact cumulus cells post-OPU have favorable influence on the em-
bryonic development compared to immediate denudation.
J. Eriksson1
What is known already: The role of cumulus cells surrounding oocytes in the
1Institute of Clinical Medicine, Department of General Practice and Primary
process of maturation, ovulation, and fertilization in mouse has been extensive-
Health Care Diabetes and Obesity Research Program Research Programs
ly studied. Prolonged culture of oocyte with intact cumulus cells has been re-
Unit, Helsinki Yliopisto, Finland
ported to induce apoptotic changes in oocytes. However, the influence of culture
Abstract text duration of oocyte with cumulus cells in human has not been investigated not
The Developmental Origins of Health and Disease (DOHaD) hypothesis pro- only on competence of oocyte, but also subsequent embryonic development.
poses that several non-communicable diseases – including coronary heart Study design, size, duration: Prospectively randomized study was performed
disease and type 2 diabetes – have their origins in prenatal life and in early on 667 oocytes retrieved from 54 patients (54 cycles) between October 2013
childhood. The intrauterine milieu which is influenced by a large number of and May 2015.
i1